Amit Dayal, an analyst from H.C. Wainwright, maintained the Buy rating on Cibus (CBUS – Research Report). The associated price target is $25.00.
Amit Dayal has given his Buy rating due to a combination of factors that highlight Cibus’s potential for growth and market expansion. The company has shown progress in its field trials, particularly in its weed management platform for Rice and Canola, which has attracted a significant portion of the market in North and Latin America. Additionally, Cibus’s advancements in bio-based fermentation products are expected to generate substantial revenue in the coming years, with management anticipating partnerships with consumer packaged goods companies by 2026.
Another factor influencing the Buy rating is the positive regulatory developments in Europe, where new genomic techniques are gaining acceptance. This regulatory shift could open up new market opportunities for Cibus, particularly in the European market, by aligning EU policies more closely with those of other major agricultural regions. The company’s strategic catalysts, including the delivery of initial traits and promising trial results, further support the potential for future growth and revenue generation.